Celgene aims to block a generic of blood cancer treatment Revlimid

08/25/2010 | Wall Street Journal, The

Celgene plans to "enforce its extensive intellectual property rights" on multiple myeloma drug Revlimid after an unnamed drugmaker filed for FDA approval of a generic version. The treatment is covered by 12 patents, with expiration as far out as 2026. Celgene has not received formal notice of the generic challenge.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN